Novo’s Answer to Retatrutide Does Well at Phase II in Type 2 Diabetes
Credit: Elva Etienne/Getty Images UBT251, the triple hormone-receptor agonist developed by United Biotechnology and licensed by Novo Nordisk…
Browsing Tag